What question did this study set out to answer?

February 5, 2026Journal of Biomaterials Science Polymer Edition0 citations

Formulation and evaluation of azithromycin loaded chitosan nanoparticles for its antibiofilm activity

CRChandana R.HAH. M. ASHVINIAl-Ameen College of Pharmacy

Key Points

This research aims to formulate and evaluate azithromycin-loaded chitosan nanoparticles for improved antimicrobial and antibiofilm efficacy.
Formulated nanoparticles by ionic gelation using chitosan and TPP.
Coated nanoparticles with PAA and cross-linked using EDC.
Characterized nanoparticles using FTIR, DSC, and electron microscopy techniques.
Conducted in-vitro drug release studies over 24 hours.
Assessed antimicrobial activity through zone of inhibition measurements against Staphylococcus aureus.
Optimized formulation exhibited a particle size of 287.3 nm and high entrapment efficiency of 98.35%.
In-vitro drug release showed sustained release of 90% over 24 hours.
Demonstrated enhanced antimicrobial activity with a zone of inhibition of 17-21 mm against Staphylococcus aureus.
Achieved 71% inhibition of biofilm biomass and a reduction of extracellular polymeric substances (EPS) by 40 µg/mL.

Abstract

The present study focused on the formulation and evaluation of azithromycin-loaded chitosan nanoparticles (AZM-CSNPs) to enhance antimicrobial and antibiofilm efficacy. The nanoparticles were prepared by ionic gelation of chitosan with TPP, followed by PAA coating and covalent conjugation using EDC cross-linking to obtain stable CTS/TPP-PAA NPs. Preformulation studies (FTIR and DSC) confirmed drug-polymer compatibility, while physicochemical characterization revealed that the optimized formulation (CNP 1) exhibited a particle size of 287.3 nm, PDI of 0.352, zeta potential of -22.0 mV, and entrapment efficiency of 98.35%. Transmission Electron Microscopy and Scanning Electron Microscopy analyses confirmed spherical, uniformly distributed nanoparticles. In-vitro drug release demonstrated sustained release of 90% over 24 h. The formulation showed enhanced antimicrobial activity against Staphylococcus aureus with a zone of inhibition of 17-21 mm and significant antibiofilm activity, evidenced by 71% biofilm biomass inhibition and 40 µg/mL EPS reduction. Overall, AZM-CSNPs displayed superior performance compared to pure azithromycin, suggesting their potential as an effective nanocarrier system for treating biofilm-associated infections and addressing antibiotic resistance.

Demander à l'IA

Bookmark

View Full Paper